MX387579B - Polipéptidos del factor vii de acción corta. - Google Patents
Polipéptidos del factor vii de acción corta.Info
- Publication number
- MX387579B MX387579B MX2016015101A MX2016015101A MX387579B MX 387579 B MX387579 B MX 387579B MX 2016015101 A MX2016015101 A MX 2016015101A MX 2016015101 A MX2016015101 A MX 2016015101A MX 387579 B MX387579 B MX 387579B
- Authority
- MX
- Mexico
- Prior art keywords
- variants
- factor vii
- short
- acting factor
- vii polypeptides
- Prior art date
Links
- 229940012413 factor vii Drugs 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title 1
- 102100023804 Coagulation factor VII Human genes 0.000 abstract 2
- 108010023321 Factor VII Proteins 0.000 abstract 2
- 208000032843 Hemorrhage Diseases 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 2
- 208000034158 bleeding Diseases 0.000 abstract 2
- 230000000740 bleeding effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 101001049020 Homo sapiens Coagulation factor VII Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000009450 sialylation Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La presente invención se refiere a un polipéptido de Factor VII variante aislado caracterizado porque comprende una secuencia de aminoácidos que tiene al menos una alteración de secuencia con respecto a la secuencia de aminoácidos de SEQ ID NO: 16, en donde al menos una alteración de secuencia se selecciona del grupo que consiste en P10Q, K32E, R36E, A34E, T106N y V253N, en donde el polipéptido tiene una proporción de moles de ácido siálico conjugado con respeto a moles de glicano unido a N de O. Un método para preparar el polipéptido de la invención y el segundo uso método del polipéptido.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745674P | 2012-12-24 | 2012-12-24 | |
| US201361787026P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/077405 WO2014105784A1 (en) | 2012-12-24 | 2013-12-23 | Short-acting factor vii polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX387579B true MX387579B (es) | 2025-03-18 |
Family
ID=51022016
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016015101A MX387579B (es) | 2012-12-24 | 2013-12-23 | Polipéptidos del factor vii de acción corta. |
| MX2015007712A MX380585B (es) | 2012-12-24 | 2013-12-23 | Polipeptidos del factor vii de acción corta. |
| MX2021002985A MX2021002985A (es) | 2012-12-24 | 2015-06-16 | Polipeptidos del factor vii de accion corta. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015007712A MX380585B (es) | 2012-12-24 | 2013-12-23 | Polipeptidos del factor vii de acción corta. |
| MX2021002985A MX2021002985A (es) | 2012-12-24 | 2015-06-16 | Polipeptidos del factor vii de accion corta. |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US20150344863A1 (es) |
| EP (3) | EP3165232B1 (es) |
| JP (3) | JP6566869B2 (es) |
| KR (2) | KR102111934B1 (es) |
| CN (2) | CN107099522A (es) |
| AU (2) | AU2013370522B2 (es) |
| BR (1) | BR112015015182B1 (es) |
| CA (2) | CA2896057C (es) |
| DK (3) | DK3572090T5 (es) |
| ES (3) | ES2746116T3 (es) |
| HK (1) | HK1216855A1 (es) |
| IL (2) | IL239345B (es) |
| MX (3) | MX387579B (es) |
| NZ (1) | NZ708873A (es) |
| PE (2) | PE20211303A1 (es) |
| PL (3) | PL2938351T3 (es) |
| SA (1) | SA517380867B1 (es) |
| SG (2) | SG11201504986QA (es) |
| TW (3) | TWI708783B (es) |
| WO (1) | WO2014105784A1 (es) |
| ZA (1) | ZA201505315B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100267508B1 (ko) | 1998-07-13 | 2001-01-15 | 김충섭 | 다겹지 제조용 접착제 및 이를 이용한 다겹지 제조방법 |
| PL2938351T3 (pl) | 2012-12-24 | 2020-03-31 | Coagulant Therapeutics Corporation | Krótko działające polipeptydy czynnika VII |
| TW201629215A (zh) * | 2014-09-30 | 2016-08-16 | 拜耳保健有限責任公司 | 使用凝血酶之組成物及治療方法 |
| KR101755838B1 (ko) | 2015-09-09 | 2017-07-07 | 현대자동차주식회사 | 엔진 예열장치 및 그 예열방법 |
| SG10202112746PA (en) * | 2016-09-13 | 2021-12-30 | Coagulant Therapeutics Corp | Factor viia glycoforms |
| KR102120921B1 (ko) * | 2017-02-10 | 2020-06-10 | 주식회사 일리아스바이오로직스 | Gba 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 고셔병 예방 및 치료용 약학적 조성물 |
| US20210069306A1 (en) | 2019-08-15 | 2021-03-11 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3008252A (en) | 1959-02-02 | 1961-11-14 | Beatrice V Robinson | Puffed sleeve ironer |
| US5180583A (en) | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
| FR2632524B1 (fr) | 1988-06-09 | 1992-03-13 | Fondation Nale Transfusion San | Procede de preparation d'une fraction concentree en facteur viia et son application a titre de medicament |
| DE60138364D1 (de) | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
| WO2001089583A2 (en) | 2000-05-23 | 2001-11-29 | Neurologix, Inc. | Glutamic acid decarboxylase (gad)_delivery system for treating neurodegenerative diseases |
| US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
| US20050221335A1 (en) | 2001-12-14 | 2005-10-06 | Anthony Kavanagh | Reporter gene |
| CN101942019A (zh) * | 2002-04-30 | 2011-01-12 | 拜耳医药保健有限公司 | 凝血因子VII或VIIa多肽变体 |
| US8512710B2 (en) | 2002-11-22 | 2013-08-20 | Ansun Biopharma, Inc. | Class of therapeutic protein based molecules |
| US7807174B2 (en) | 2002-11-22 | 2010-10-05 | Nexbio, Inc. | Class of therapeutic protein based molecules |
| JP4847856B2 (ja) * | 2003-03-20 | 2011-12-28 | バイエル ヘルスケア エルエルシー | ＦＶＩＩおよびＦＶＩＩａの変種 |
| EP1644504B8 (en) * | 2003-06-19 | 2010-06-02 | Bayer HealthCare LLC | Factor vii or viia gla domain variants |
| US20060198819A1 (en) * | 2003-08-08 | 2006-09-07 | Novo Nordisk Healthcare A/G | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
| CN1863908B (zh) * | 2003-09-09 | 2010-08-04 | 诺和诺德医疗保健公司 | 凝固因子ⅶ多肽 |
| EP1725673A1 (en) | 2004-02-13 | 2006-11-29 | Glycotope Gmbh | Sialytated glycoproteins-process conditions and an efficient method for their production |
| AU2005240741A1 (en) | 2004-05-10 | 2005-11-17 | Basf Plant Science Gmbh | Methods for assembling multiple expression constructs |
| WO2005123916A2 (en) * | 2004-06-21 | 2005-12-29 | Novo Nordisk Health Care Ag | Glycosylation-disrupted factor vii variants |
| WO2006094810A2 (en) | 2005-03-11 | 2006-09-14 | Fresenius Kabi Deutschland Gmbh | Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch |
| EP1893230A2 (en) * | 2005-04-26 | 2008-03-05 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| PL1907540T3 (pl) * | 2005-07-22 | 2013-05-31 | Bayer Healthcare Llc | Aktywacja czynnika VII w roztworze |
| AU2006280932A1 (en) | 2005-08-19 | 2007-02-22 | Novo Nordisk A/S | Glycopegylated factor VII and factor Vila |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| WO2007054783A2 (en) * | 2005-11-08 | 2007-05-18 | Astellas Pharma Inc. | Compositions and methods for treating thrombocytopenia |
| EA015942B1 (ru) * | 2006-05-05 | 2011-12-30 | Милленниум Фамэсьютикэлс, Инк. | Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови |
| FR2901707B1 (fr) | 2006-05-31 | 2017-09-29 | Lab Francais Du Fractionnement | Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis |
| US7532621B2 (en) | 2006-08-30 | 2009-05-12 | Cornell Research Foundation, Inc. | Lateral error correction for time-critical multicast |
| CN101557830B (zh) * | 2006-12-15 | 2016-06-08 | 巴克斯特国际公司 | 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物 |
| US20100026939A1 (en) | 2006-12-20 | 2010-02-04 | Sumitomo Chemical Company, Limited | Polarizer and liquid crystal display device |
| MX2009007139A (es) | 2006-12-28 | 2009-10-08 | Centocor Ortho Biotech Inc | Metodos y vectores para generar inmunoglobulinas no sialiladas. |
| NZ578882A (en) | 2007-02-20 | 2012-01-12 | Dsm Ip Assets Bv | Sialidase from the fungus Penicilium chrysogenum |
| WO2008134665A1 (en) | 2007-04-26 | 2008-11-06 | Inspiration Biopharmaceuticals, Inc. | Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same |
| EP2195444B9 (en) | 2007-10-12 | 2015-09-16 | Sigma-Aldrich Co. LLC | Cell line and methods for improved glycoprotein sialylation |
| TWI538916B (zh) * | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
| US8557773B2 (en) * | 2008-05-02 | 2013-10-15 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Treatment of bleeding with low half-life fibrinogen |
| JP2010022253A (ja) * | 2008-07-17 | 2010-02-04 | Kaneka Corp | アシアロ糖鎖化合物の作製方法 |
| WO2010065735A2 (en) | 2008-12-05 | 2010-06-10 | The Regents Of The University Of California | Methods and compositions for treating p.acnes |
| US8400974B2 (en) * | 2009-07-30 | 2013-03-19 | Apple Inc. | Methods and apparatus for providing dynamic information in a wireless information channel |
| US20130196410A1 (en) | 2010-03-05 | 2013-08-01 | Alnylam Pharmaceuticals, Inc | Compositions and methods for modifying the glycosylation pattern of a polypeptide |
| WO2013017555A1 (en) * | 2011-08-01 | 2013-02-07 | Lfb-Biotechnologies | Factor vii compositions with specific glycosylation for controlled half-life |
| PL2938351T3 (pl) | 2012-12-24 | 2020-03-31 | Coagulant Therapeutics Corporation | Krótko działające polipeptydy czynnika VII |
-
2013
- 2013-12-23 PL PL13867801T patent/PL2938351T3/pl unknown
- 2013-12-23 MX MX2016015101A patent/MX387579B/es unknown
- 2013-12-23 AU AU2013370522A patent/AU2013370522B2/en active Active
- 2013-12-23 PL PL19181784.0T patent/PL3572090T3/pl unknown
- 2013-12-23 HK HK16104910.1A patent/HK1216855A1/zh unknown
- 2013-12-23 NZ NZ70887313A patent/NZ708873A/en unknown
- 2013-12-23 ES ES13867801T patent/ES2746116T3/es active Active
- 2013-12-23 BR BR112015015182-5A patent/BR112015015182B1/pt active IP Right Grant
- 2013-12-23 EP EP16196780.7A patent/EP3165232B1/en active Active
- 2013-12-23 EP EP13867801.6A patent/EP2938351B8/en active Active
- 2013-12-23 PE PE2020001539A patent/PE20211303A1/es unknown
- 2013-12-23 MX MX2015007712A patent/MX380585B/es unknown
- 2013-12-23 JP JP2015549857A patent/JP6566869B2/ja active Active
- 2013-12-23 DK DK19181784.0T patent/DK3572090T5/da active
- 2013-12-23 SG SG11201504986QA patent/SG11201504986QA/en unknown
- 2013-12-23 WO PCT/US2013/077405 patent/WO2014105784A1/en not_active Ceased
- 2013-12-23 PE PE2015001020A patent/PE20151206A1/es unknown
- 2013-12-23 CN CN201610960730.5A patent/CN107099522A/zh active Pending
- 2013-12-23 EP EP19181784.0A patent/EP3572090B1/en active Active
- 2013-12-23 ES ES19181784T patent/ES2936485T3/es active Active
- 2013-12-23 SG SG10201710593UA patent/SG10201710593UA/en unknown
- 2013-12-23 US US14/654,581 patent/US20150344863A1/en not_active Abandoned
- 2013-12-23 KR KR1020197017382A patent/KR102111934B1/ko active Active
- 2013-12-23 DK DK16196780.7T patent/DK3165232T3/da active
- 2013-12-23 CA CA2896057A patent/CA2896057C/en active Active
- 2013-12-23 DK DK13867801.6T patent/DK2938351T3/da active
- 2013-12-23 KR KR1020157019457A patent/KR102047235B1/ko active Active
- 2013-12-23 CN CN201380073743.5A patent/CN105025913B/zh active Active
- 2013-12-23 ES ES16196780T patent/ES2747726T3/es active Active
- 2013-12-23 PL PL16196780T patent/PL3165232T3/pl unknown
- 2013-12-23 CA CA3185756A patent/CA3185756A1/en active Pending
- 2013-12-24 TW TW108101456A patent/TWI708783B/zh active
- 2013-12-24 TW TW108130396A patent/TWI743542B/zh active
- 2013-12-24 TW TW102147863A patent/TWI681968B/zh active
-
2014
- 2014-07-25 US US14/341,359 patent/US10273466B2/en active Active
-
2015
- 2015-06-11 IL IL239345A patent/IL239345B/en active IP Right Grant
- 2015-06-16 MX MX2021002985A patent/MX2021002985A/es unknown
- 2015-06-23 SA SA517380867A patent/SA517380867B1/ar unknown
- 2015-07-23 ZA ZA2015/05315A patent/ZA201505315B/en unknown
-
2016
- 2016-09-14 US US15/265,703 patent/US10717970B2/en active Active
- 2016-10-28 JP JP2016211992A patent/JP6363677B2/ja active Active
-
2019
- 2019-04-16 AU AU2019202663A patent/AU2019202663B2/en active Active
- 2019-07-30 JP JP2019139775A patent/JP2019213540A/ja active Pending
-
2020
- 2020-03-24 IL IL273559A patent/IL273559B/en unknown
- 2020-06-09 US US16/896,646 patent/US11530401B2/en active Active
-
2022
- 2022-11-08 US US18/053,577 patent/US20230295596A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX380585B (es) | Polipeptidos del factor vii de acción corta. | |
| PH12019500694A1 (en) | Factor viii compositions and methods of making and using the same | |
| EA201591839A1 (ru) | Терапевтические пептиды | |
| IL294314A (en) | Proteins based on the scaffolding domain of fibronectin that bind to myostatin | |
| PH12017500939A1 (en) | T cell activating bispecific antigen binding molecules agiant folr1 and cd1 | |
| HK1206638A1 (zh) | 用於生产化妆品蛋白质和肽的修饰的多核苷酸 | |
| EA201591367A1 (ru) | Соединения резорцина для дерматологического применения | |
| PH12014501736B1 (en) | Therapeutic use of p75ntr neurotrophin binding protein | |
| PH12014501604A1 (en) | Polypeptides binding to human complement c5 | |
| MY198233A (en) | Protease-Activated T Cell Bispecific Molecules | |
| EP3747457A3 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| MX390894B (es) | Polipéptido de fusión anti-cáncer. | |
| MX377781B (es) | Composiciones y metodos para diagnostico y tratamiento del cancer. | |
| WO2014140103A3 (en) | Thrombin sensitive coagulation factor x molecules | |
| WO2015084883A3 (en) | Compositions and methods for treating osteoarthritis | |
| MX2013001836A (es) | Proteina de fusion de fc recombinante del quinto dominio tipo iii de fibronectina de ddc. | |
| NZ729181A (en) | Treatment of disease with poly-n-acetylglucosamine nanofibers | |
| WO2013109190A3 (en) | Cho-gmt recombinant protein expression | |
| MX373466B (es) | Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion. | |
| MX2020013410A (es) | Proteinas prohemostaticas para el tratamiento de hemorragias. | |
| PH12016501132A1 (en) | A process for preparing a composition of pegylated proteins | |
| WO2014115087A3 (en) | A method for the preparation of recombinant human prothrombin and fibrinogen | |
| CY1119117T1 (el) | Δερμοπροστατευτικη και δερμο-εξισορροπητικη συνθεση | |
| AR118705A2 (es) | Polipéptido del factor vii para tratar enfermedades, método para prepararlo y composición que lo contiene | |
| WO2015057583A8 (en) | Treatment of chronic kidney disease with sahps |